Provided by Tiger Trade Technology Pte. Ltd.

Molecular Partners AG

4.32
+0.30007.46%
Post-market: 4.26-0.0600-1.39%16:10 EST
Volume:1.49K
Turnover:6.29K
Market Cap:161.56M
PE:-2.12
High:4.34
Open:4.25
Low:4.25
Close:4.02
52wk High:5.99
52wk Low:3.36
Shares:37.40M
Float Shares:14.89M
Volume Ratio:1.49
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0363
EPS(LYR):-1.7524
ROE:-51.41%
ROA:-27.01%
PB:1.36
PE(LYR):-2.47

Loading ...

Molecular Partners presents new MP0712 data

TIPRANKS
·
Nov 12

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

GlobeNewswire
·
Nov 12

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

GlobeNewswire
·
Nov 03

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

GlobeNewswire
·
Nov 03

Molecular Partners Q3 EPS $(1.65) Misses $(0.46) Estimate

Benzinga
·
Oct 31

Press Release: Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Dow Jones
·
Oct 31

Molecular Partners Q2 EPS $(0.67) Down from $(0.56) YoY

Benzinga
·
Aug 26

Press Release: Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Dow Jones
·
Aug 26

Molecular Partners AG expected to post a loss of 45 rappen a share - Earnings Preview

Reuters
·
Aug 22

Molecular Partners Names Martin Steegmaier as Chief Scientific Officer

MT Newswires Live
·
Aug 21

Press Release: Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

Dow Jones
·
Aug 21

Molecular Partners Reports Complete Responses in Updated Data From Blood Cancer Study

MT Newswires Live
·
Jun 12

Molecular Partners to Reduce up to 24% of Workforce

MT Newswires Live
·
Jun 10